Company Sponsored Symposia
Company Sponsored Symposia
Sunday, 2 June 2019
| Company Sponsored Symposium (CSS 1) Allergy Therapeutics plc. 10:30 – 12:00, Hall 5 |
 |
Transforming Allergy Treatment
Chair: Dolores Hernández F. de Rojas, Spain
Evolution of Allergen Immunotherapy
Speaker: Lawrence DuBuske, United States
Venom Immunotherapy
Speaker: Jörg Kleine-Tebbe, Germany
The hygiene Hypothesis; stepping into the spotlight
Speaker: Erika Jensen-Jarolim, Austria
| Company Sponsored Symposium (CSS 2) Aimmune Therapeutics 12:05 – 13:25, Hall 8 |
 |
111 years of oral immunotherapy: Progress in the development of treatment for food allergy using OI
Chair: Margitta Worm, Germany
Chair’s Welcome and Introduction: EU Anaphylaxis Registry – Update
Speaker: Margitta Worm, Germany
Recent Research Advances in the Management of Peanut Allergy
Speaker: Pablo Rodríguez del Río, Spain
OIT Experience in France
Speaker: Amandine Divaret-Chauveau, France
Q&A Panel Discussion
| Company Sponsored Symposium (CSS 3) Novartis 13:30 – 15:00, Hall 5 |
 |
The treatment gap in asthma and morbidities: advances in targeting IgE and DP2receptor
Chair: Marc Humbert, France
Welcome and introduction
Speaker: Marc Humbert, France
Advances in targeting IgE
An overview of the biology of targeting IgE and its clinical translation to asthma treatment
Speaker: Marc Humbert, France
Nasal polyps and allergic rhinitis: The role of targeting IgE
Speaker: Martin Wagenmann, Germany
What is the role of IgE in chronic urticaria?
Speaker: Marcus Maurer, Germany
Advances in targeting the DP2receptor
Overview of the DP2receptor pathway and its role in inflammation
Speaker: Christian Domingo, Spain
Chair-led expert discussion and audience Q&A
Summary and close
Speaker: Marc Humbert, France
| Company Sponsored Symposium (CSS 4) Sanofi Genzyme and Regeneron 15:30 – 17:00, Hall 5 |
 |
Exploring the Multiple Facets of Type 2 Inflammation in Uncontrolled Persistent Asthma: A New Approach in Asthma Management
Learning objectives:
This interactive symposium will explore the impact of type 2 inflammation in patients with uncontrolled persistent asthma, including the underlying pathophysiology, benefits and limitations of inflammatory biomarkers, and the challenges faced by physicians when selecting a biologic treatment strategy—using case studies, panel discussion, and Q&A to consolidate learnings. The latest clinical data on biologics will be presented, focusing on the key asthma control goals of reducing exacerbations and oral corticosteroid (OCS) use, and improving lung function and quality of life.
Chair: Eric Bateman, South Africa
Welcome and Introduction
Speaker: Eric Bateman, South Africa
Type 2 Inflammation in Asthma: Understanding Pathophysiology and the Role of Biomarkers
Speaker: Klaus Rabe, Germany
Current and New Treatment Options for Uncontrolled Persistent Asthma with Type 2 Inflammation
Speaker: Ian Pavord, United Kingdom
Importance of Reducing OCS Use in Patients with Asthma
Speaker: Eric Bateman, South Africa
Case-based Discussions—Unravelling Asthma Phenotypes and Endotypes: New Considerations for Patient Identification and Biologic Selection – All Faculty
Closing Remarks and Q&A – All Faculty
Speaker: Eric Bateman, South Africa
Monday, 3 June 2019
| Company Sponsored Symposium (CSS 5) ALK 10:45 – 12:15, Hall 14 |
 |
Chair: Victoria Cardona, Spain
AIT formulation – does it matter?
Speaker: Natalija Novak, Germany
Immunological cross-reactivity and clinical relevance of the SQ tree SLIT-tablet
Speaker: Tilo Biedermann, Germany
Can we use biomarkers to predict AIT response in allergic asthma?
Speaker: Eugene Bleecker, United States
Clinical relevance of immunology in AIT – your questions answered
Speaker: Stephen Durham, United Kingdom
| Company Sponsored Symposium (CSS 6) Mylan 12:20 – 13:40, Hall 4 |
 |
Chair: Nikolaos Papadopoulos, United Kingdom
Introduction
Speaker: Nikolaos Papadopoulos, United Kingdom
May I introduce?! – Nasal Hyper Responsiveness
Speaker: Peter Hellings, Belgium
New data on comorbid Asthma patients: AR treatment improves Asthma outcomes
Speaker: David Price, Australia
Reliever medication for AIT Patients
Speaker: Claus Bachert, Belgium
The new targets in the new ARIA guideline
Speaker: Jean Bousquet, France
Conclusion – All
| Company Sponsored Symposium (CSS 7) HAL Allergy 13:45 – 15:15, Hall 8 |
 |
Chair: Ronald van Ree, Netherlands
Chair: Dirk-Jan Opstelten, Netherlands
Food allergy treatment: Current State and Future Options
Speaker: James R. Baker Jr. , United States
Mite AIT: What’s next?
Speaker: Moisés Antonio Calderón, United Kingdom
Allergy Therapy and Prevention in 2030
Speaker: Johann Christian Virchow, Germany
Wrap-Up
Speaker: Ronald van Ree, Netherlands
| Company Sponsored Symposium (CSS 8) Allergopharma GmbH & Co. KG 15:45 – 17:15, Hall 8 |
 |
FASIT* – we can work it out! –*Future of the Allergists and Specific Immunotherapy
Chair: Oliver Pfaar, Germany
Chair: Stephen Durham, United Kingdom
AIT – ready to become standard asthma treatment?
Speaker: Graham Roberts, United Kingdom
AIT in rhinitis – what is the regulators’ view?
Speaker: Vera Mahler, Germany
AIT in 2024 – where is the journey taking us?
Speaker: Carsten Schmidt-Weber, Germany
Tuesday, 4 June 2019
| Company Sponsored Symposium (CSS 9) Thermo Fisher Scientific 10:30 – 12:00, Hall 14 |
 |
Learning objectives:
To improve the knowledge among health care providers and scientists about the role of IgE antibodies in respiratory allergy and food allergy.
To inform the latest scientific news about allergen components with focus on tree nuts, sesame, red meat, house dust mite, grass pollen, and dog and cat dander.
To present the state of the art knowledge about how allergen sensitization patterns can be used as an aid in clinical diagnosis of allergy and asthma.
Chair: Paolo Matricardi, Germany
Molecular allergology in asthma – The use of mite and grass pollen components
Speaker: Paolo Matricardi, Germany
New diagnostic tools for allergy to furry animals and red meat
Speaker: Marianne van Hage, Sweden
Allergen components in pediatric food allergy diagnosis
Speaker: Anna Nowak-Wegrzyn, United States
Allergen microarrays and sensitization algorithms for prediction of asthma
Speaker: Adnan Custovic, United Kingdom
Summary and future directions
Speaker: Paolo Matricardi, Germany
| Company Sponsored Symposium (CSS 10) Stallergenes Greer 12:05 – 13:25, Hall 4 |
 |
Learning objectives:
Share specific evidences that public health burden of chronci allergic disease is increasing in terms of prevalence, complexity and severity.
Chair: Thomas Casale, United States
Chair: Moisés Calderón, United Kingdom
Burden of HDM allergic respiratory diseases
Speaker: Petra Zieglmayer, Austria
Precision medicine to optimize patient outcomes
Speaker: Philippe Gevaert, Belgium
The 300IR “solution” and future trends
Speaker: Pascal Demoly, France
| Company Sponsored Symposium (CSS 11) AstraZeneca UK Ltd 13:30 – 15:00, Hall 9 |
 |
Chair: Sameer Mathur, United States
Welcome and Introductions
Asthma Heterogeneity: Understanding the Eosinophilic Phenotype
Speaker: João Almeida Fonseca, Portugal
Emerging Evidence and the Evolving Therapeutic Landscape
Speaker: Stephanie Korn, Germany
Insights From Patient Cases
Speaker: Sameer Mathur, United States
Panel Discussion and Audience Q&A
| Company Sponsored Symposium (CSS 12) Novartis 15:30 – 17:00, Hall 8 |
|
The many faces of mastocytosis, from interdisciplinary diagnosis to treatment strategies, and an insight into the patient’s journey
Chair: Frank Siebenhaar, Germany
Welcome
Speaker: Frank Siebenhaar, Germany
Mastocytosis – a disease with many faces
Speaker: Frank Siebenhaar, Germany
An interdisciplinary approach and diagnostic measures for mastocytosis
Speaker: Sigurd Broesby-Olsen, Denmark
Clinical hallmarks and therapeutic strategies for advanced systemic mastocytosis
Speaker: Andreas Reiter, Germany
Insights into the patient’s journey – experience from patient groups
Speaker: Jess Hobart, United Kingdom
Insights into the patient’s journey – experience from patient groups
Speaker: Andrew Dugdale, United Kingdom
Closing remarks
Speaker: Frank Siebenhaar, Germany